IL6 and Abnormal retinal morphology: Furthermore, cytokine inhibitors, such as TNF-α blockers (adalimumab, infliximab), IL-6 antagonists (tocilizumab), and IL-1β inhibitors (canakinumab), are being actively explored for their potential to reduce chronic inflammation in retinal diseases.